ClinicalTrials.gg
Enrolling by invitationNCT07860801Updated Nov 17, 2026

Study of Vaping Use Among Adolescent and Young Adult Patients With Cancer

An observational study in Cancer and Vaping, sponsored by Memorial Sloan Kettering Cancer Center. Enrolling by invitation at 7 sites in United States. Open to participants aged 15 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Memorial Sloan Kettering Cancer Center · Observational

How we know

Updated Oct 8, 2026Now Enrolling by invitationPrimary outcomes revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
80
Ages
15 Years and older
Sex
All
01

Study summary

The purpose of this study is to learn more about how adolescent and young adult (AYA) cancer patients, their parents and caregivers (referred to as a carebuddy in this study), and their healthcare providers think about and communicate around vaping and tobacco use. The researchers hope this information will help them develop educational materials and provider training tools that are appropriate for young people with cancer.

A Community Advisory Board that is made up of AYA patients, parents/caregivers, and healthcare providers, is helping to guide the study. The board will review the materials, give feedback, help the study team understand the findings, and provides input to make sure the study is appropriate and practical for participants.

02

Conditions studied

  • Cancer
  • Vaping

Keywords

  • Vaping
  • Tobacco Treatment Program
  • 26-337
  • Focus groups
  • Surveys
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 80 is below the median of 200 across 2,644 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,964 studies on the registry; 325 are open to participants now.

Of its 135 completed or terminated interventional studies of FDA-regulated products, 71 (53%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

MSK clinics

Eligibility criteria

Inclusion Criteria:

  • Inclusion criteria for Patients:
  • History of cancer diagnosis;
  • Report vaping within the past 12 months as documented in the medical record, clinician note, and/or self-report;
  • Age 15-39 years at date of consent;
  • Receiving or have received treatment at MSK;
  • Iidentify English as primary language as per medical record
  • Inclusion criteria for Parents/Carebuddy (i.e., family member, friend):
  • Self-report they are the parent/carebuddy of an AYA patient who currently or previously vaped.
  • Inclusion criteria for Oncology Providers:
  • Conducts ≥2 AYA clinical consultations weekly as per self-report or EMR;
  • Is an MSK clinician (i.e., nurse practitioner, social worker, physician assistant, physician)

Exclusion Criteria:

  • Exclusion criteria for Patients:
  • Acute psychiatric symptoms impairing participation as per the EMR or as per clinician judgment;
  • Reports exclusive use of combustible or smokeless tobacco products (i.e., no history of nicotine vaping).
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
80 participants (estimated)
Patient registry
No

Groups and cohorts

  • Adolescent / Young Adult (AYA) who have or had cancer

    Other: Study assessments

  • Carebuddy of an Adolescent / Young Adult (AYA)

    Other: Study assessments

  • Healthcare providers of Adolescent / Young Adult (AYA)

    Other: Study assessments

Interventions

  • OtherStudy assessments

    Patient and Parent/Carebuddy Survey, Provider Survey, AYA Patient Focus Group Guide, Parent/Caregiver Focus Group Guide. AYA patient and parent/carebuddies participants will participate in virtual focus group sessions conducted via Zoom or Microsoft Teams. Focus groups will utilize structured discussion guides informed by talk-aloud (think-aloud) methodology. The research staff will maintain communication with participants before their focus groups via call, email, text and/or MyChart before their focus groups to remind them about their upcoming focus group as well as to have their computers charged.

06

What researchers measure

Primary outcomes

  1. support needs to inform the development of developmentally appropriate vaping cessation resources.

    using study assessments Survey measures will include: 1) Sociodemographic and medical characteristics (e.g., age, race/ethnicity, education, employment status/role); 2) vaping use and knowledge, including frequency of use, product type, and related perceptions; and 3) for providers only, current communication practices related to vaping use among AYA patients, perceived barriers, educational needs, and suggested adaptations to provider communication training materials.

    Time frame: 1 year

07

Study locations

7 sites
08

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Sep 2027, 12 months after the start.

Of 1,099 non-industry observational studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 227. This study's planned 12 months is below that.

Counting every sponsor, half of 1,247 studies reached it within 58 months; a quarter within 24 and three quarters within 210.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2026
First posted
Oct 6, 2026
StartActual
Sep 30, 2026
Primary completionEst.
Sep 30, 2027
CompletionEst.
Sep 30, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Enrolling by invitation
changed Oct 8, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • Descriptionsupport needs to inform the development of developmentally appropriate vaping cessation resources.: how it is measured was reworded
Oct 8, 2026
Contact
No study contact listed any more: removed b•••@mskcc.org · •••0158; removed •••0011
Oct 8, 2026
Registered
First appeared on the registry
Oct 6, 2026
Show all 4 updates
  1. Nov 17, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 16, 2026
    Minor edits only
    + 2 other changes: description and arm descriptions
  3. Oct 8, 2026
    Recruiting→Enrolling by invitation
    Primary outcomes 1 description edited
    What changed in the outcomes
    • Descriptionsupport needs to inform the development of developmentally appropriate vaping cessation resources.: how it is measured was reworded
    Contact No study contact listed any more: removed b•••@mskcc.org · •••0158; removed •••0011
    + 2 other changes: verification date and site details
  4. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07860801
Responsible party
Sponsor
First posted
Oct 6, 2026
Start date
Sep 30, 2026
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Gleneara Bates-Pappas, PhD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion